Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes

Nova Mentis (NOVA) was studying the effect of psilocybin on rats with autism symptoms when they discovered an unexpected finding…

Not only did the psilocybin improve anxiety and cognitive function in the rats, but it also seemed to impact the proteins that regulate inflammation, indicating that the formulation may be able to treat obesity and diabetes related to obesity (“diabesity”).

Another highly promising indicator is that psilocybin activates the 5-HT2C serotonin receptors, which play a role in body weight and food intake. In fact, one of the current FDA-approved obesity treatments called lorcaserin is also a serotonin receptor agonist, but it can have lots of unwanted side effects that psilocybin would likely avoid!